Merck & Co's Gefapixant Cuts Chronic Cough in Phase III

But Concerns Over Taste Side Effects

 
• By Kevin Grogan

New data puts Merck & Co's P2X3 receptor antagonist ahead of the field but Bellus Health's rival in the class may benefit from issues over taste alteration with gefapixant.

Coughing
Prevalence Of Chronic Cough Estimated At 10% Of Adults Globally • Source: Shutterstock

More from Clinical Trials

More from R&D